

August 22, 2023

Sean McCarthy, D.Phil.  
Chief Executive Officer  
CytomX Therapeutics, Inc.  
151 Oyster Point Blvd., Suite 400  
South San Francisco, CA 94080

Therapeutics, Inc.

Statement on Form S-3  
2023

Re: CytomX

Registration

Filed August 16,

File No. 333-274010

Dear Sean McCarthy:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Hagius at 202-551-7967 with any questions.

Please contact Dillon

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Mark Roeder